Boehringer Ingelheim

This early-phase trial tests a new medicine, BI 765049, in adults with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The main goal is to find the highest safe dose and best way to give the drug. BI 765049 is designed to help t…

This study tests whether adding a new drug called obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults will be randomly assigned to get either the new combo or standard treatment alone. The goal is t…

This study tests a new medicine called BI 3802876 in 30 adults with liver scarring (cirrhosis) caused by MASH, a fatty liver disease. The goal is to see if the drug is safe and how the body processes it. Participants get either the drug or a placebo by IV infusion twice over 6 mo…

This study tests a new drug called BI 764532 (obrixtamig) in adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to prior treatment. The drug is designed to help the immune system attack cancer cells. The study aims to find the best…

This study looks at the long-term safety of a daily pill called nerandomilast for people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). About 1,700 adults who finished a previous nerandomilast study can join. They take the drug for up to 22 mont…

This early-stage study tests a new drug called BI 3810944 in adults with advanced solid tumors or melanoma who have run out of treatment options. The goal is to find safe doses and see if the drug can shrink tumors. Participants receive the drug every three weeks, with more frequ…

This early-phase study tests a new drug, BI 3923948, in adults with advanced solid tumors that have spread and are not responding to other treatments. The drug is given alone or with an immunotherapy (checkpoint inhibitor) to find the safest dose and see if it can shrink tumors. …

This study tests whether empagliflozin, a medicine already used for diabetes, can help children aged 2 to 17 with chronic kidney disease (CKD). About 120 kids will be randomly assigned to take the drug or a placebo for 6 months, then all will receive the drug for another year. Re…

This study tests a medicine called survodutide in 1590 adults with NASH or MASH cirrhosis, a serious liver condition. Participants receive either the drug or a placebo as a weekly injection for up to 4.5 years, along with diet and exercise advice. The goal is to see if survodutid…

This early-phase study tests a new drug called obrixtamig in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker (DLL3). The goal is to find the safest dose and schedule. Participants receive the drug weekly or every 3 weeks for…

This study tests a daily tablet called BI 1291583 in adults and teens aged 12 and older with bronchiectasis, a lung condition that causes frequent infections and breathing problems. The goal is to see if the medicine reduces the number of serious flare-ups compared to a placebo. …

This study tests a new medicine called BI 765423 in people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. About 71 adults aged 40 and older will receive either the drug or a placebo by IV every 4 weeks for 3 months. The main …

This study tests an experimental tablet, BI 764198, in adults and some teens with four types of kidney disease that cause protein in the urine. About 132 participants will be randomly assigned to take the drug or a placebo once daily for 20 weeks, while continuing their usual tre…

This study tests a new drug, BI 1703880, combined with ezabenlimab for adults with advanced solid tumors who have no other treatment options. The goal is to find the highest safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then e…

This study tests a daily oral drug called zongertinib for adults with advanced solid tumors that have HER2 mutations or overexpression. Participants must have already tried other treatments without success. The goal is to see if zongertinib can shrink tumors and control the disea…

This study checks if two versions of the drug survodutide work the same way in the body. It involves 80 healthy adults who are overweight or have obesity. Participants will receive both formulations at different times to compare how the drug is absorbed and processed.

This study tests a new drug, BI 3820768, in adults with advanced germ cell, endometrial, or ovarian cancers that have not responded to prior treatments. The drug aims to help the immune system fight cancer. Participants receive weekly injections for two 3-week cycles, then every …

This early-phase study tests an experimental drug (BI 764532) added to standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC) whose tumors have a specific marker (DLL3). The main goals are to find safe dose levels and see if the combination helps shrink tum…

This study tests an experimental oral drug called zongertinib, which blocks HER2 (a protein that fuels cancer growth). It is given alone or with other standard treatments to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and no longer responds to…

This study tests whether adding vicadrostat to standard heart failure medication (empagliflozin) helps adults with chronic heart failure and a weak heart pump. About 4200 participants will take either the combination or a placebo plus empagliflozin daily for up to 3.5 years. Rese…

This study tests a medicine called survodutide, given as a weekly injection, in 1800 adults with NASH/MASH and moderate to advanced liver fibrosis. The goal is to see if it can improve or reverse liver damage and prevent progression to cirrhosis. Participants receive either survo…

This study tests whether adding vicadrostat to the standard drug empagliflozin helps people with heart failure who have a preserved ejection fraction (LVEF ≥40%). About 6000 adults with symptoms will be randomly assigned to receive either the combination or a placebo plus empagli…

This study tests a medicine called nerandomilast for people with lung scarring caused by autoimmune diseases like rheumatoid arthritis or scleroderma. About 400 adults who still have lung problems despite standard treatment will take either the drug or a placebo for at least 26 w…

This study tests a new daily pill (BI 764198) for people with a rare kidney disease called FSGS. About 286 adults and teens will take either the study drug or a placebo for up to 2 years, while continuing their usual treatments. The goal is to see if the drug reduces protein in t…

This study tests an oral medicine called BI 1815368 for people with diabetic macular edema, a condition that causes vision loss. About 300 adults will take either the study drug or a placebo twice daily for 11 months. Researchers will measure if the treatment improves vision by a…

This study tests whether adding vicadrostat to the standard drug empagliflozin can lower the chance of heart problems or death in adults with type 2 diabetes, high blood pressure, and heart disease. About 11,800 participants will take either the combination or a placebo plus empa…

This study tests an experimental oral medicine, BI 3000202, in 405 adults with moderate to severe systemic lupus erythematosus (SLE). Participants are randomly assigned to one of four doses of BI 3000202 or a placebo, taken daily for a year, while continuing their usual lupus tre…

This study tests if spesolimab can close painful skin ulcers in adults with pyoderma gangrenosum, a rare inflammatory condition. About 90 participants will receive either the drug or a placebo, along with oral steroids for the first 8 weeks. The main goal is complete ulcer closur…

This study tests a medicine called nerandomilast in people aged 40 and older who have early lung changes and a family history of pulmonary fibrosis. Participants take the drug or a placebo twice daily for about 2-3 years. The goal is to see if the drug can slow or prevent worseni…

This study looks at how pirfenidone changes the amount of another medicine, BI 1015550, in the blood of adults with idiopathic pulmonary fibrosis (IPF). Twenty participants aged 40 and older will take both drugs over about a month, with frequent blood tests and clinic visits. The…

This early-stage study tests the safety and how the body handles a new drug called BI 3821001. It involves 72 healthy men aged 18 to 55. Participants receive either a single dose of the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blo…

This study tests whether a single dose of vicadrostat affects the heart's electrical activity in 45 healthy adults aged 18 to 50. Participants receive vicadrostat, placebo, or moxifloxacin in a crossover design. The goal is to compare heart rhythm changes, ensuring the drug is sa…

This early-stage trial tests a new drug called BI 3804379 in healthy adults aged 18 to 65. The goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo as a shot under the skin. The study does not aim to treat any disea…

This study looks at how a single dose of the experimental drug BI 1291583 enters the blood in people with and without liver problems. The drug is being developed for bronchiectasis, a chronic lung disease. About 32 adults aged 18–80 will take one tablet and be monitored for about…

This early-stage study tests a new medicine, BI 456906, in 30 adults with obesity. It uses special scans to see how the drug attaches to receptors in the liver and pancreas that control appetite and weight. Participants receive either BI 456906 or the approved weight-loss drug se…

This study looks at how a medicine called BI 3000202 behaves in the body of people with and without liver problems. About 44 adults aged 18 to 80 will take one tablet and have their blood tested over a month. The goal is to understand if liver impairment changes how the drug work…

This study looks at how often lung scarring (interstitial lung disease) happens in people with rheumatic diseases like rheumatoid arthritis or lupus in Mexico. Researchers will track 312 adults over time to see what factors make the lung disease worse. No new treatments are given…

This early-stage study is testing a new drug called BI 3776528 in healthy male volunteers to see if it is safe and how the body handles it. About 142 men aged 18 to 50 will receive either the drug or a placebo. The goal is to gather safety information, not to treat any disease.

This study is for adults with advanced small cell lung cancer or other neuroendocrine cancers that haven't responded to standard treatments. Researchers want to see how the experimental drug BI 764532 moves through the body and gets absorbed by tumors using special PET scans. Abo…

This early-stage study is testing a new drug called BI 3031185 in 60 healthy men aged 18 to 50. The goal is to see if the drug is safe and how the body processes it when taken by mouth multiple times. Participants will be randomly assigned to receive either the drug or a placebo,…